Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leo van der Pol

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Biotechnology Journal|February 26, 2016
Outer membrane vesicles as platform vaccine technologyLeo van der Pol, Michiel Stork, Peter van der Ley
Vaccine|May 8, 2014
Efficient chromatographic reduction of ovalbumin for egg-based influenza virus purificationHans Blom, Anna Åkerblom, Theone Kon, et al.
Biotechnology Advances|May 20, 2017
Bioengineering bacterial outer membrane vesicles as vaccine platformMatthias J H Gerritzen, Dirk E Martens, René H Wijffels, et al.
Biotechnology and Bioengineering|May 1, 2009
Gene-expression-based quality scores indicate optimal harvest point in Bordetella pertussis cultivation for vaccine productionBas van de Waterbeemd, Mathieu Streefland, Jeroen Pennings, et al.
Vaccine|May 21, 2010
Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification processBas van de Waterbeemd, Mathieu Streefland, Peter van der Ley, et al.
Expert Review of Vaccines|February 7, 2009
Quality-control issues and approaches in vaccine developmentBernard Metz, Germie van den Dobbelsteen, Cécile van Els, et al.
Plos One|March 10, 2016
Influenza Vaccine Manufacturing: Effect of Inactivation, Splitting and Site of Manufacturing. Comparison of Influenza Vaccine Production ProcessesTheone C Kon, Adrian Onu, Laurentiu Berbecila, et al.
Tuberculosis (Edinburgh, Scotland)|December 14, 2020
The TB vaccine development pathway - An innovative approach to accelerating global TB vaccine developmentDanielle Roordink, Ann Williams, Bernard Fritzell, et al.
Trends in Biotechnology|May 10, 2025
Engineered thermoswitch in the baculovirus expression vector system for production of virus-like particle vaccines with minimized baculovirus contaminantsLinda van Oosten, Jort J Altenburg, Gwen Nowee, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Biotechnology Journal|February 26, 2016
Outer membrane vesicles as platform vaccine technologyLeo van der Pol, Michiel Stork, Peter van der Ley
Vaccine|May 8, 2014
Efficient chromatographic reduction of ovalbumin for egg-based influenza virus purificationHans Blom, Anna Åkerblom, Theone Kon, et al.
Biotechnology Advances|May 20, 2017
Bioengineering bacterial outer membrane vesicles as vaccine platformMatthias J H Gerritzen, Dirk E Martens, René H Wijffels, et al.
Biotechnology and Bioengineering|May 1, 2009
Gene-expression-based quality scores indicate optimal harvest point in Bordetella pertussis cultivation for vaccine productionBas van de Waterbeemd, Mathieu Streefland, Jeroen Pennings, et al.
Vaccine|May 21, 2010
Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification processBas van de Waterbeemd, Mathieu Streefland, Peter van der Ley, et al.
Expert Review of Vaccines|February 7, 2009
Quality-control issues and approaches in vaccine developmentBernard Metz, Germie van den Dobbelsteen, Cécile van Els, et al.
Plos One|March 10, 2016
Influenza Vaccine Manufacturing: Effect of Inactivation, Splitting and Site of Manufacturing. Comparison of Influenza Vaccine Production ProcessesTheone C Kon, Adrian Onu, Laurentiu Berbecila, et al.
Tuberculosis (Edinburgh, Scotland)|December 14, 2020
The TB vaccine development pathway - An innovative approach to accelerating global TB vaccine developmentDanielle Roordink, Ann Williams, Bernard Fritzell, et al.
Trends in Biotechnology|May 10, 2025
Engineered thermoswitch in the baculovirus expression vector system for production of virus-like particle vaccines with minimized baculovirus contaminantsLinda van Oosten, Jort J Altenburg, Gwen Nowee, et al.
Pageof 1